Short‐term outcomes of a COVID‐adapted triage pathway for colorectal cancer detection

Aim The dramatic curtailment of endoscopy and CT colonography capacity during the coronavirus pandemic has adversely impacted timely diagnosis of colorectal cancer (CRC). We describe a rapidly implemented COVID‐adapted diagnostic pathway to mitigate risk and maximize cancer diagnosis in patients referred with symptoms of suspected CRC. Method The ‘COVID‐adapted pathway’ integrated multiple quantitative faecal immunochemical tests (qFIT) to enrich for significant colorectal disease with judicious use of CT with oral contrast to detect gross pathology. Patients reporting ‘high‐risk’ symptoms were triaged to qFIT+CT and the remainder underwent an initial qFIT to inform subsequent investigation. Demographic and clinical data were prospectively collected. Outcomes comprised cancer detection frequency. Results Overall, 422 patients (median age 64 years, 220 women) were triaged using this pathway. Most (84.6%) were referred as ‘urgent suspicious of cancer’. Of the 422 patients, 202 (47.9%) were triaged to CT and qFIT, 211 (50.0%) to qFIT only, eight (1.9%) to outpatient clinic and one to colonoscopy. Fifteen (3.6%) declined investigation and seven (1.7%) were deemed unfit. We detected 13 cancers (3.1%), similar to the mean cancer detection rate from all referrals in 2017–2019 (3.3%). Compared with the period 1 April–31 May in 2017–2019, we observed a 43% reduction in all primary care referrals (1071 referrals expected reducing to 609). Conclusion This COVID‐adapted pathway mitigated the adverse effects on diagnostic capacity and detected cancer at the expected rate within those referred. However, the overall reduction in the number of referrals was substantial. The described risk‐mitigating measures could be a useful adjunct whilst standard diagnostic services remain constrained due to the ongoing pandemic.